Pulmozyme, dornase alfa is a targeted therapy designed for patients with cystic fibrosis (CF). By breaking down viscous secretions in the lungs, the drug can significantly improve respiratory function and reduce the risk of infection.

What diseases can Pulmozyme (dornase alfa) dornase inhaler treat?

Improve respiratory function in patients with cystic fibrosis

Dornase alfa reduces sputum viscosity by hydrolyzing DNA, helping patients expel airway secretions. Clinical studies have shown that patients who use a 2.5mg dose daily can increase their vital capacity (FVC) by 5%-10%, and their dyspnea symptoms are significantly relieved. It is suitable for children and adults aged ≥5 years with FVC ≥40% of the predicted value.

Reduce the risk of respiratory infections

Long-term use of this drug can reduce the incidence of respiratory infections requiring parenteral antibiotics by 28%. For CF patients with recurrent pneumonia or bronchiectasis, Dornase Alfa(Pulmozyme) combined with standard therapy can effectively reduce the number of acute attacks and prolong the stable period.

Clarifying the indications is the basis for rational drug use. The following content will explain the necessity and precautions for long-term use of the drug.

Does Dornase Alfa(Pulmozyme) need to be used for a long time?

Cystic fibrosis is a chronic genetic disease that requires lifelong management. Alfa deoxyribonuclease inhaler is a core treatment option and usually requires long-term regular use to maintain efficacy.

Daily medication continuity

The recommended dose is 2.5mg (single vial) once a day, inhaled through a jet nebulizer or a vibrating mesh nebulizer. Interruption of treatment may lead to re-accumulation of sputum and decreased lung function. Studies have shown that patients who continue to use the drug for more than 6 months have a 34% lower hospitalization rate than those who do not use the drug regularly.

Long-term management of special populations

Children need to complete daily nebulization treatment under parental supervision to ensure that the drug is fully deposited in the lungs. Although it is rare in elderly CF patients, attention should be paid to refrigerated storage conditions (2°C-8°C). Long-term medication requires reasonable planning of drug procurement and storage.

Long-term treatment requires a combination of standardized operations and regular evaluation. The following content will answer the question of hormone components that patients are concerned about.

Does Dornase Alfa inhaler contain hormones?

Dornase Alfa inhaler does not contain any hormone components. Its main active ingredient is recombinant human deoxyribonuclease (dornase alfa). The drug acts directly on DNA in sputum through enzymatic hydrolysis, without relying on hormone anti-inflammatory mechanisms.

Analysis of ingredient safety

Each 2.5mL solution contains 2.5mg dornase alfa and excipients such as sodium chloride and water for injection. It does not contain glucocorticoids, antibiotics or other immunomodulators, and long-term use will not cause hormone-related side effects (such as osteoporosis and increased blood sugar).

Applicability to special populations

Pregnant women and breastfeeding women can use it after evaluation by a doctor. Existing data do not show that it poses a clear risk to the fetus or infant. Children need to use an appropriate nebulizer (such as the eRapid system) to avoid drug waste caused by mask inhalation.

Correctly understanding the composition and mechanism of action of the drug will help patients eliminate concerns about medication. During treatment, the nebulizer cleaning process must be strictly followed and lung function should be checked regularly. If mild reactions such as hoarseness and pharyngitis occur, there is usually no need to stop the drug, and the symptoms usually resolve on their own within a week. Through doctor-patient collaboration and scientific management, Dornase Alfa(Pulmozyme) can provide lasting lung protection for CF patients.